Premium
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high‐risk follicular lymphoma due to severe haematological and infectious toxicity
Author(s) -
Cheah Chan Y.,
Nastoupil Loretta J.,
McLaughlin Peter,
Fanale Michelle A.,
Neelapu Sattva S.,
Fayad Luis E.,
Hagemeister Frederick B.,
Fowler Nathan H.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13863
Subject(s) - medicine , bendamustine , rituximab , mitoxantrone , follicular lymphoma , adverse effect , tolerability , common terminology criteria for adverse events , fludarabine , neutropenia , oncology , surgery , lymphoma , gastroenterology , cyclophosphamide , chemotherapy